Epigenomics AG operates in the Diagnostic substances sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Epigenomics AG with three other
pharmaceutical manufacturers in Europe:
sales of 1.74 million Slovak Koruny [US$2.05 million]
of which 1,172%
Summit Therapeutics PLC
of the United Kingdom
(£2.30 million [US$3.10 million]
of which 100%
was Drug Discovery), and
based in France
(2.31 million Euro [US$2.71 million]
Epigenomics AG reported sales of 1.86 million Euro (US$2.19 million)
December of 2017.
decrease of 55.6%
versus 2016, when the company's sales were 4.20 million Euro.
Contributing to the drop in overall sales was the 75.2% decline
in Products Sales (Own and Third Party), from 2.21 million Euro to 548,000.00 Euro.
There were also decreases in sales in
Research and Development (down 39.2% to 45,000.00 Euro)
However, these declines were partially offset by the increase in sales of
Licenses (up 125.4% to 1.27 million Euro)